Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | PHASE3 | RECRUITING | 400 | — | — | Aug 5, 2025 | Nov 4, 2030 | May 6, 2026 | 202 | United States, Australia +25 |
| Arm | Type | Description |
|---|---|---|
| Arm A: PF-07248144 plus fulvestrant | OTHER | PF-07248144 tablet taken by mouth plus fulvestrant taken as a shot into the muscle. |
| Arm B: everolimus plus ET | ACTIVE_COMPARATOR | Everolimus tablet taken by mouth plus investigator's choice of endocrine therapy of exemestane tablet taken by mouth or fulvestrant taken as a shot into the muscle. |
| Name | Type | Description |
|---|---|---|
| PF-07248144 | DRUG | KAT6 inhibitor |
| Fulvestrant | DRUG | Endocrine therapy |
| Everolimus | DRUG | mTOR inhibitor |
| Exemestane | DRUG | Endocrine therapy |
Inclusion Criteria: * Confirmed diagnosis of HR-positive HER2-negative breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Prior CDK4/6 inhibitor therapy in combination with endocrine therapy...